Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;71(2):469-77.
doi: 10.1111/biom.12287. Epub 2015 Mar 27.

Longitudinal clinical trials with adaptive choice of follow-up time

Affiliations

Longitudinal clinical trials with adaptive choice of follow-up time

Neal Jeffries et al. Biometrics. 2015 Jun.

Abstract

In longitudinal studies comparing two treatments with a maximum follow-up time there may be interest in examining treatment effects for intermediate follow-up times. One motivation may be to identify the time period with greatest treatment difference when there is a non-monotone treatment effect over time; another motivation may be to make the trial more efficient in terms of time to reach a decision on whether a new treatment is efficacious or not. Here, we test the composite null hypothesis of no difference at any follow-up time versus the alternative that there is a difference at at least one follow-up time. The methods are applicable when a few measurements are taken over time, such as in early longitudinal trials or in ancillary studies. Suppose the test statistic Z(t(k)) will be used to test the hypothesis of no treatment effect at a fixed follow-up time t(k). In this context a common approach is to perform a pilot study on N1 subjects, and evaluate the treatment effect at the fixed time points t1,…,t(K) and choose t* as the value of t(k) for which Z(t(k)) is maximized. Having chosen t* a second trial can be designed. In a setting with group sequential testing we consider several adaptive alternatives to this approach that treat the pilot and second trial as a seamless, combined entity and evaluate Type I error and power characteristics. The adaptive designs we consider typically have improved power over the common, separate trial approach.

Keywords: Adaptive design; Adaptive follow-up time; Adaptive longitudinal trial; Longitudinal study; Model-free longitudinal analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Temporal availability of test statistics

References

    1. Armitage P, Stratton IM, Worthington HV. Repeated significance tests for clinical trials with a fixed number of patients and variable follow-up. Biometrics. 1985;41:353–359. - PubMed
    1. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994;50:1029–1041. - PubMed
    1. Geary DN. Sequential testing in clinical trials with repeated measurements. Biometrics. 1998;75:311–318.
    1. Genz A, Fretz F, Miwa T, Mi X, Leisch F, Scheipl F, Hothorn T. mvtnorm: Multivariate Normal and t Distributions. 2012 R package version 0.9-9992. http://CRAN.R-project.org/package=mvtnorm.
    1. Glimm E, Maurer W, Bretz F. Hierarchical testing of multiple endpoints in group sequential trials. Statistics in Medicine. 2010;29:219–228. - PubMed